Osteoporosis Treatment Global Market Report 2024

The osteoporosis treatment market size has grown strongly in recent years. It will grow from $13.16 billion in 2023 to $13.87 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth observed in the historical period can be attributed to several factors, including demographic shifts towards an aging population, the widespread adoption of hormone replacement therapies, increased utilization of calcium and vitamin D supplementation, advancements in diagnostic tools, and the integration of digital health solutions.

The osteoporosis treatment market size is expected to see steady growth in the next few years. It will grow to $16.6 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The projected growth in the forecast period is driven by the escalation of sedentary lifestyles, a heightened prevalence of secondary osteoporosis, the emergence of virtual bone fracture clinics, advancements in gene therapy for osteoporosis, and an increased emphasis on men's bone health. Key trends anticipated in the forecast period involve progress in biologics, the incorporation of artificial intelligence, the utilization of blockchain for bone health records, and the integration of machine learning.

The anticipated growth of the osteoporosis treatment market is driven by the increasing prevalence and incidence of osteoporosis. Osteoporosis, a bone disease characterized by changes in bone strength, composition, and a decrease in bone mass and mineral density, is addressed by various drugs that slow down bone deterioration. Hormone-based treatments, particularly estrogen post-menopause, help maintain bone density. Amgen reported in May 2022 that the annual number of fractures due to osteoporosis is projected to rise by 68% to 3.2 million by 2040, emphasizing the market's growth potential.

The growth of the osteoporosis treatment market is fueled by the escalating healthcare expenditures. Healthcare expenditures encompass the total spending on healthcare services and products within a specific timeframe. Osteoporosis treatment contributes significantly to the rising healthcare costs, covering expenses for diagnostic tests, medications, rehabilitation services, and potential surgeries. In November 2022, the CIHI projected a 0.8% increase in total health spending in Canada, from $328 billion in 2021 to $331 billion in 2022, underscoring the market's expansion facilitated by the surge in healthcare expenditures.

A prevailing trend in the osteoporosis treatment market is the increasing emphasis on product innovation, with major companies actively adopting recent technologies to fortify their market positions. In January 2021, Theramex, a UK-based pharmaceutical company, exemplified this trend by introducing Livogiva, a novel teriparatide pre-filled pen designed for the treatment of severe osteoporosis. Positioned as a biosimilar to the reference drug Forsteo, Livogiva demonstrated therapeutic equivalence in a phase III clinical investigation, showcasing the company's commitment to technological advancements.

Leading companies in the osteoporosis treatment market are strategically focusing on the development of derivative capsules, particularly those containing vitamin D3, to attain a competitive advantage. In December 2022, Chugai Pharmaceutical Co., Ltd., based in Tokyo, collaborated with Towa Pharmaceutical, a Japan-based counterpart, to launch 'Edirol Tablets 0.5 µg/0.75 µg.' These capsules, featuring an active vitamin D3 derivative, are tailored for the treatment of osteoporosis. Specifically designed to enhance bone and calcium metabolism, Edirol Tablets aim to reduce vertebral fractures and increase bone mineral density, exemplifying the companies' commitment to cutting-edge solutions.

In May 2023, Abiogen Pharma, an Italy-based specialist in osteoarticular and bone metabolism diseases, acquired a 97.09% stake in EffRx Pharmaceuticals. This strategic acquisition, conducted for an undisclosed amount, serves to strengthen Abiogen Pharma's global presence and underscores its dedication to bone health and rare diseases. EffRx Pharmaceuticals, headquartered in Switzerland, possesses a portfolio that includes products for the treatment of postmenopausal osteoporosis, aligning with Abiogen Pharma's broader objectives in the field.

Major companies operating in the osteoporosis treatment market report are Pfizer Inc., F. Hoffmann La Roche Ltd., Merck and Co Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline Pharmaceutical Ltd., Takeda Pharmaceutical Company, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Corporation, AstraZeneca Plc., Viatris Inc., Allergan PLC, Teva Pharmaceuticals Industries Ltd., Biogen Inc., Daiichi Sankyo company Ltd., Dr. Reddy's Laboratories, Gedeon Richter Plc., Celltrion Inc., Luye Pharma Group, Covis Pharmaceuticals Inc., Ligand Pharmaceuticals Incorporated, Radius Health Inc., Haoma Medica Ltd., Actavis PLC, EffRx Pharmaceuticals SA.

North America was the largest region in the osteoporosis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the osteoporosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the osteoporosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Key pharmaceuticals involved in osteoporosis treatment include bisphosphonates, calcitonin, hormone therapy, selective estrogen receptor modulators (SERMs), parathyroid hormone-related protein (PTHrP) analog, and rank ligand (RANKL) inhibitor. Bisphosphonates, recognized for their efficacy in relieving bone discomfort associated with certain cancers and hypercalcemia, are pivotal in preventing osteoporotic fractures. These medications can be administered orally, through injections, and other modalities, with distribution channels spanning hospitals, retail pharmacies, stores, and online pharmacies.

The osteoporosis treatment research report is one of a series of new reports that provides osteoporosis treatment market statistics, including the osteoporosis treatment industry's global market size, regional shares, competitors with osteoporosis treatment market share, detailed osteoporosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the osteoporosis treatment industry. This osteoporosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The osteoporosis treatment market consists of revenues earned by entities by providing osteoporosis services such as physical therapy and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteoporosis treatment market also includes sales of alendronate, risedronate, Ibandronate, and zoledronic acid. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.